Navigation Links
DURECT Corporation Announces Third Quarter 2010 Financial Results
Date:11/3/2010

m clinical trials for our drug candidates, our failure to achieve the performance milestones or commercial sales that trigger the referenced payments or royalties under our collaborative agreements, our (and that of our third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to development activities and products, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced drug candidates, consummate collaborative agreements relating to our drug candidates and technologies, manufacture and commercialize the referenced drug candidates, obtain marketplace acceptance of the referenced drug candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on August 5, 2010 under the heading "Risk Factors."DURECT CORPORATIONSTATEMENT OF OPERATIONS DATA(in thousands, except per share amounts)(Unaudited)Three months ended Nine months ended September 30, September 30, 2010200920102009Collaborative research and development and other revenue

$
5,689$
3,027$
4,162$
9,545Product revenue, net

2,4275,3518,93310,037Total revenues

8,1168,37823,09519,582Operating expenses:Cost of product revenues (1)

8592,8343,0984,495Research and development (1)

8,1427,59826,76725,534Selling, general and administrative (1)

3,8063,55410,89211,588Total operating expenses

12,80713,98640,75741,617Loss from operations

(4,691)(5,608)(17,662)(22,035)Other income (expense):Interest and other income

4682105367Interest and other expense

(2)(9)(25)(31)Net other income 447380336Net loss$
(4,647)$
(5,535)$
(17,582)$
(21,699)Net loss per share, basic and diluted

$
(0
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
2. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
3. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
4. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
5. DURECT to Present at the Jefferies Global Life Sciences Conference
6. DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
7. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
8. DURECT to Present at the Barclays Capital Global Healthcare Conference
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
11. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Transportation ... provider, announces winning the SDCE100 Award for ... & Demand Chain Executive magazine. Transportation ... consumer goods distributor quantify and control supply ... their highly competitive market. Deploying Transportation Insight,s ...
(Date:5/28/2015)... 28, 2015   Eli Lilly and Company (NYSE: ... host a webcast on June 11 to discuss data from ... rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will ... the EULAR Congress 2015 in Rome, Italy ... to11:00 a.m. Eastern Daylight Time. The live audio webcast can ...
(Date:5/28/2015)... , May 28, 2015 ... "Global mHealth Market (Device, Service, Application, Stakeholders and Geography) - ... 2014-2020", stated that the global mHealth market was ... expected to grow at a CAGR of 33.5% ... share in the global mHealth device market followed ...
Breaking Medicine Technology:Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 3Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 4Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 2mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 3mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 4
... Therapeutics Inc. today announced results from a Phase ... lesion growth and preserves visual acuity in patients with ... age-related macular degeneration ( AMD ). The data showed ... levels of 60 percent to 75 percent was predictive ...
... The New Hampshire Bio/Medical Council held its 2nd Annual Awards Dinner ... NH. During the evening, the Bio/Medical Council awarded Atrium Medical Corporation ... Business of the Year Award. In attendance ... Chief Operating Officer and Steve Vail, Group VP of Global Marketing. ...
Cached Medicine Technology:Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients 2Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients 3Atrium Recognized by New Hampshire Bio/Medical Council 2
(Date:5/29/2015)... Pastor and Overseer, Yisrayl Hawkins, at The House of Yahweh ... The Creator was removed and replaced, and how religious leaders ... years the Name of the Creator in most bibles was ... original writings. He adds that there was a conspiracy to ... deception and intentionally mislead people. , “I know this may ...
(Date:5/29/2015)... New England Peptide, Inc. (NEP), in ... Analysis Consortium (CPTAC) and others, today announced the ... of peptide stable isotope standards for biomarker discovery. ... tryptic peptides, offers thousands of fragments spanning over ... accessible to the biomedical research community. Each ...
(Date:5/28/2015)... Richmond, Kentucky (PRWEB) May 29, 2015 Recently, ... focused on helping amputees regain their quality of life. The ... who may have had one for years, but are still ... there are nearly 2 million people living with limb loss ... vascular disease (54%) – including diabetes and peripheral arterial disease ...
(Date:5/28/2015)... The partners of Urgent Care of Westchester and ... Almendral as their chief provider for advanced beauty treatments. ... opened facility’s plan to offer all of Westchester County ... Almendral is a board certified physician who is trained ... techniques. Her areas of expertise include Botox, Dermal Fillers, ...
(Date:5/28/2015)... 28, 2015 On Sunday, June 21, ... a team event to honor the strength, passion and ... summer solstice, the duration of this sunrise-to-sunset event symbolizes ... and their caregivers. Participants raise funds and awareness to ... Alzheimer’s Association. , Teams are encouraged to create their ...
Breaking Medicine News(10 mins):Health News:In New Post This Week, Yisrayl Hawkins Praises Religious Leaders For Confessing Yahweh Is The Name Of The Creator 2Health News:New England Peptide Announces New Tryptides™ Catalog 2Health News:New England Peptide Announces New Tryptides™ Catalog 3Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2
... Calif., Sept. 10 Genomic,Health, Inc. (Nasdaq: ... that,support the use of quantitative real-time polymerase chain ... for measuring the hormone,receptors, estrogen receptor (ER) and ... separate study identified multiple genes,including the 21 genes ...
... (NYSE:,ABT) -- the global health care company -- ... and the Dow Jones Sustainability North America,Index for ... leadership in business, environmental and social performance. ... to business," said,Miles D. White, chairman and chief ...
... Board is ,Best Suited, to Conclude Merger and Manage ... Waiting Period, READING, Pa., Sept. 10 Arrow ... of catheter-based access and,therapeutic products for critical and cardiac ... advisory firm, is advising its clients to,approve Arrow,s planned ...
... inadequate for those who have undergone total knee ... of Nursing researcher. , Barbara Rakel Ph.D., assistant ... million grant from the National Institute of Nursing ... and pharmacologic strategies to improve movement-evoked pain and ...
... LAS VEGAS and BEIJING, Sept. 10 /Xinhua-PRNewswire-FirstCall/ ... a development stage company with,the goal of ... company and,engaged in multiple China-focused business activities ... today announced that the Company has appointed ...
... JOLLA, CA In the cerebral cortex, the brains ... subdivisions known as areas are laid out like a ... that shape the geography of our brains. , ... an international collaboration between researchers at the Salk Institute ...
Cached Medicine News:Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2Health News:Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting 2Health News:Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting 3Health News:China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc. 2Health News:China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc. 3Health News:Researchers uncover novel mechanism that balances the sizes of functional areas in the brain 2Health News:Researchers uncover novel mechanism that balances the sizes of functional areas in the brain 3
Stylish, elegant and feminine, these attractive frames provide refined and beautiful styles for women ages 40 and older....
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
The latest MAX MARA eyewear collection has evolved into a harmonious balance of tradition and,leading-edge trend, interpreting timeless themes in an absolutely modern way, yet never losing sight,...
The Liz Claiborne eyewear collection features feminine, classic, progressive friendly designs that meet the needs of today's women. The high quality frames are modern, but not trendy....
Medicine Products: